In short
A new clinical trial is underway to assess the effectiveness of a drug called GLSI-100, which combines GP2 (a HER2/neu peptide) with GM-CSF, for patients with HER2-positive breast cancer. This study focuses on patients who have a high risk of disease recurrence after completing standard treatments. The trial aims to determine if GLSI-100 can improve outcomes for these patients compared to a placebo.
At a glance
- Study Type
- Phase 3, randomized, multicenter, placebo-controlled
- Drug Name
- GLSI-100 (GP2 + GM-CSF)
- Target Population
- HER2-positive breast cancer patients with high risk of recurrence
- Main Eligibility Criteria
- HLA-A*02 positive, completed neoadjuvant and adjuvant trastuzumab-based therapy
- Primary Endpoint
- Invasive Breast Cancer-Free Survival (IBCFS)
- Secondary Endpoints
- Invasive Disease-Free Survival (IDFS), Overall Survival (OS), Quality of Life, Safety
- Treatment Duration
- Up to 36 months
- Administration Route
- Intradermal injection
What is GLSI-100?
GLSI-100 is a potential new therapy for HER2-positive breast cancer. It consists of two components:
- GP2: A peptide (small protein fragment) also known as L-ISOLEUCYL-L-ISOLEUCYL-L-SERYL-L-ALANYL-L-VALYL-L-VALYL-GLYCYL-L-ISOLEUCYL-L-LEUCINE
- GM-CSF: Granulocyte-macrophage colony-stimulating factor, also called sargramostim
This combination is being studied as a potential treatment to prevent the recurrence of breast cancer in patients who have already completed standard treatments.
Target Population
GLSI-100 is designed for patients with HER2-positive breast cancer who:
- Have completed both neoadjuvant (before surgery) and adjuvant (after surgery) trastuzumab-based therapy
- Have a high risk of disease recurrence, including:
- Patients with stage I, II, or III cancer at initial diagnosis who have residual disease after surgery
- Patients with stage III cancer at initial diagnosis who achieved a pathologic complete response (pCR) after surgery
How GLSI-100 Works
GLSI-100 is designed to stimulate the immune system to recognize and attack HER2-positive cancer cells:
- GP2 is a peptide that mimics part of the HER2 protein found on breast cancer cells
- GM-CSF helps activate immune cells
- Together, they aim to "train" the immune system to recognize and eliminate any remaining cancer cells, potentially preventing recurrence
Clinical Trial Details
A phase 3 clinical trial called FLAMINGO-01 is currently studying GLSI-100:
- It is a randomized, multicenter, placebo-controlled study
- The main goal is to assess how effective GLSI-100 is compared to a placebo in preventing breast cancer recurrence
- The study will measure Invasive Breast Cancer-Free Survival (IBCFS), which is the time from starting the treatment until the cancer returns or the patient dies from any cause
Eligibility Criteria
To participate in the FLAMINGO-01 trial, patients must meet specific criteria, including:
- HER2-positive breast cancer diagnosis
- Completed standard trastuzumab-based therapy
- No current evidence of cancer
- Able to start the study treatment within one year of completing standard therapy
- Adequate organ function
Some factors that may exclude patients from participating include:
- Stage IV or metastatic breast cancer
- Inflammatory breast cancer
- Currently receiving chemotherapy or other investigational treatments
- History of serious allergic reactions to similar treatments
Potential Benefits
If successful, GLSI-100 could offer several benefits to patients:
- Reduced risk of breast cancer recurrence
- Improved overall survival
- Better quality of life for breast cancer survivors
Safety and Side Effects
The FLAMINGO-01 trial will closely monitor the safety of GLSI-100:
- Researchers will track the frequency and severity of side effects
- Side effects will be categorized using standardized criteria (NIH CTCAE, version 5.0)
- The study will assess how these side effects relate to the treatment
It's important to note that as this is an ongoing clinical trial, the full safety profile of GLSI-100 is not yet known. Patients considering participation should discuss potential risks and benefits with their healthcare provider.